Results 271 to 280 of about 797,089 (324)

Moderna mRNA therapy passes safety test

C&EN Global Enterprise, 2019
Moderna has published its first peer-reviewed study testing the safety of its messenger RNA molecules for therapeutic-protein production in humans. The small, Phase I trial, conducted in collaboration with AstraZeneca, showed that an experimental mRNA ...
R. Cross
semanticscholar   +2 more sources

BioNTech gets funds for mRNA therapy, more

C&EN Global Enterprise, 2019
BioNTech, the German drug company best known for its experimental messenger RNA therapies, has raised $325 million in series B financing to move more of its drug candidates to the clinic and build up its manufacturing capacity.
R. Cross
semanticscholar   +2 more sources

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Advances in Materials, 2023
Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA vaccines (Comirnaty and Spikevax).
Yan Zong, Yi Lin, Tuo Wei, Qiang Cheng
semanticscholar   +1 more source

Nobel-Honored mRNA Tech Advancing Cancer Therapy

Cancer Discovery, 2023
Abstract The discovery of chemical alterations to mRNA, work recognized by the 2023 Nobel Prize in Physiology or Medicine, is helping to advance a new frontier of clinical-stage vaccines and therapeutic candidates for cancer.
openaire   +2 more sources

mRNA-based therapies: Preclinical and clinical applications

2022
At the fundamental level, messenger RNA (mRNA)-based therapeutics involves the delivery of in vitro-transcribed (IVT) mRNA into the cytoplasm of a target cell, where it is translated into the desired protein. IVT mRNA presents various advantages compared to DNA and recombinant protein-based approaches that make it ideal for a broad range of therapeutic
Musga, Qureischi, Julia, Mohr, Estibaliz, Arellano-Viera, Sarah Elspeth, Knudsen, Farrukh, Vohidov, Andoni, Garitano-Trojaola   +5 more
openaire   +2 more sources

Exosome-mRNA therapy for Gaucher disease

Molecular Genetics and Metabolism, 2016
M. Tarnopolsky, T. Rupar, J. Rip, Aisha Nazli, A. Safdar   +4 more
semanticscholar   +2 more sources

An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy

Advances in Materials, 2022
Among the few available mRNA delivery vehicles, lipid nanoparticles (LNPs) are the most clinically advanced but they require cumbersome four components and suffer from inflammation‐related side effects that should be minimized for safety.
Pei Huang, Lingsheng Jiang, Hui-Ting Pan, Lingwen Ding, Bo Zhou, Mengyao Zhao, Jianhua Zou, Benhao Li, Meiwei Qi, Hongzhang Deng, Yongfeng Zhou, Xiaoyuan Chen   +11 more
semanticscholar   +1 more source

Next‐gen mRNA‐enhanced Cell Therapy

The FASEB Journal, 2020
A new therapeutic field is emerging as obstacles are overcome to the clinical applications of mRNA drugs. The immunogenicity of mRNA has been reduced by the use of modified nucleosides and ultra‐purification. The stability and translatability of mRNA is increased by attention to optimizing codon use, the translational ramp, the 3′ and 5′UTRs, and by ...
John P. Cooke, Anahita Mojiri, Rhonda Holgate, Brandon Walther, Hongye Li, Colleen Stubbs, Yi Liang, Celetta Callaway, Palas Chanda, Tulsi Damase, Claudia Kettlun-Leyton, Dan Kiss, Roman Sukhovershin   +12 more
openaire   +1 more source

Lipid nanoparticle-assisted mRNA therapy for cancer treatment

Applied Physics Reviews
mRNA technology and the lipid nanoparticle (LNP) platform have gained significant research attention for other therapeutic applications, particularly cancer treatment, after the success of COVID-19 mRNA vaccines.
Hyun-Jin Kim, N. Le, Hyun-Ji Oh, Beomsu Kim, Eunjae Yoo, Jeonghwan Kim, H. Yim   +6 more
semanticscholar   +1 more source

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

The Lancet
BACKGROUND Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with ...
Jeffrey Weber, M. Carlino, A. Khattak, Tarek M. Meniawy, G. Ansstas, M. Taylor, Kevin B. Kim, M. Mckean, G. V. Long, Ryan J. Sullivan, M. Faries, T. Tran, C. Cowey, A. Pecora, M. Shaheen, J. Segar, T. Medina, Victoria Atkinson, G. Gibney, J.J. Luke, S. Thomas, E. Buchbinder, Jane Healy, Mo Huang, M. Morrissey, Igor Feldman, Vasudha Sehgal, C. Robert-Tissot, Peijie Hou, Lili Zhu, Michelle Brown, Praveen Aanur, R. Meehan, T. Zaks   +33 more
semanticscholar   +1 more source